FLUO Share Price Performance
SEK 0
-38.20 (-100.00%)
Price SEK 0
Fair ValueSEK 59.12
Share Pricen/a
FluoGuide A/S Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
FLUO Community Narratives
AN
Fair Value
·Fair Value SEK 59.12 40.5% undervalued intrinsic discount
Regulatory Alignment And Phase II Success Will Support A Wider Surgical Imaging Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
FluoGuide
40.5% undervalued intrinsic discount
Regulatory Alignment And Phase II Success Will Support A Wider Surgical Imaging Opportunity
View narrativeAN
Updated 17 Aug
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
FLUO: Positive Cancer Surgery Trial Data Will Support Future Upside
Fair Value: SEK 59.12 40.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
FluoGuide A/S Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 26, 2026
- -2.83
- 100.00%
- -16,945.79%
- 87.9%
About FLUO
- Founded
- 2018
- Employees
- 7
- CEO
- WebsiteView website
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer. The company was incorporated in 2018 and is based in Copenhagen, Denmark.
